Skip to content

Hero image: A woman having a relaxed and respectful sexual health consultation with a female clinician

All insights

Sexual wellbeing

Sexual Wellbeing and Female Sexual Dysfunction: A Biopsychosocial Standard of Care

12 min readEvidence synthesis
Read the evidence

The question in focus

A respectful, evidence-based guide to desire, arousal, orgasm, pain, menopause-related symptoms and individualized sexual health care.

Evidence at a glance

12%

of women in a large US survey reported a sexual problem accompanied by personal distress

The PRESIDE study surveyed 31,581 women. Sexual concerns without distress were more common, which is why diagnosis should consider distress, context and preference rather than frequency alone. [2]

Sexual problems and distress in United States women

Sexual health is broader than dysfunction

WHO defines sexual health as physical, emotional, mental and social wellbeing in relation to sexuality, not merely the absence of disease or dysfunction. It includes respect, safety, freedom from coercion and discrimination, and the possibility of pleasurable and safe experiences. [1] This framing avoids making partnered sex, orgasm frequency or a particular level of desire into a universal standard.

A concern becomes clinically relevant when it is unwanted, distressing or associated with pain, safety risk, relationship difficulty or another health condition. People vary in desire, identity, orientation, relationship structure and goals. Asexuality is not a disorder. Clinicians should ask what the person wants to change and what satisfying sexual wellbeing means to them.

  • Use inclusive, non-assumptive language.
  • Ask permission before discussing or examining intimate concerns.
  • Separate consensual variation from distressing dysfunction.

Prevalence depends on distress and definition

The PRESIDE study surveyed 31,581 US women. Although sexual problems were commonly reported, a problem accompanied by clinically defined personal distress occurred in 12.0% overall and was highest among women aged 45 to 64 at 14.8%. [2] These figures are not universal and depend on the questionnaire, culture, health and sample.

The distinction matters. Low desire can be appropriate in a stressful, painful or unwanted context and may not need treatment. Conversely, a less common symptom may deserve urgent attention if it reflects trauma, infection, medication harm or severe pain. Assessment should not reduce experience to a prevalence statistic.

  • Ask about distress, duration and change from the person's baseline.
  • Clarify whether the concern is desire, arousal, orgasm, pain, sensation or relationship context.
  • Screen for coercion and violence privately and safely.

Assessment should be biopsychosocial

The ISSWSH process of care begins with universal permission to discuss concerns, then elicits the story, names or reframes the issue, responds empathically and proceeds to assessment, treatment or referral. [3] History can cover medical and surgical conditions, pregnancy and postpartum changes, menopause, pelvic floor symptoms, medications, mood, trauma, relationship context and cultural beliefs.

Examination or testing should be guided by symptoms and consent. Pain may require evaluation for infection, dermatologic disease, genitourinary syndrome of menopause, endometriosis, vulvodynia or pelvic floor dysfunction. ACOG notes that people often do not raise sexual concerns unless clinicians ask and that care may include medical, psychological and relationship approaches. [4]

  • Review antidepressants, hormonal medicines and other drugs that can affect sexual function.
  • Ask about dryness, bleeding, urinary symptoms and pain location.
  • Use trauma-informed examination and allow the patient to stop.
  • Refer beyond personal expertise.

Treatment follows the cause and the goal

Management may include education, lubricants or moisturizers, pelvic floor physiotherapy, psychosexual therapy, relationship counseling, medication review and treatment of a specific medical condition. The best plan may combine approaches because biological, psychological and interpersonal factors interact. Claims for supplements, hormones or devices should be matched to diagnosis, evidence and regulatory status.

For genitourinary syndrome of menopause, options can include nonhormone moisturizers and lubricants, low-dose vaginal estrogen or other prescription therapies after individualized review. The Menopause Society's position statement notes that evidence is insufficient to confirm safety of vaginal energy-based devices for this indication. [5] Persistent bleeding, lesions or unexplained pain require clinical assessment rather than repeated retail treatment.

  • Treat pain before prescribing more sexual activity.
  • Set a patient-defined outcome rather than a performance target.
  • Discuss benefits, adverse effects, contraindications and alternatives.
  • Reassess if treatment changes desire but not distress or wellbeing.

Pelvic health and safety deserve routine attention

Pelvic floor muscles can be overactive, underactive, painful or poorly coordinated. Generic strengthening can worsen pain for some people, so assessment by a trained pelvic health professional is important. NICE recommends symptom-specific non-surgical management and supervised pelvic floor muscle training in appropriate conditions. [6]

A high-quality sexual health service protects confidentiality, offers private screening for coercion, supports diverse identities and provides referral to gynecology, dermatology, pelvic health, menopause care, mental health or sexual medicine. Outcomes should include pain, distress, function, satisfaction with care and safety, not a standardized frequency of sex.

  • Can the person discuss concerns without a partner present?
  • Is pelvic floor treatment tailored to relaxation, coordination or strength?
  • Are interpreters trained in confidential sexual health communication?
  • Does the service respond safely to abuse or coercion disclosure?

What the evidence cannot yet answer

  • Prevalence estimates vary by definition, instrument, culture, age and sampling.
  • Sexual wellbeing is personally and culturally contextual; population averages are not treatment targets.
  • Evidence is limited for many supplements, devices and combination treatments.
  • Sexual symptoms can reflect multiple simultaneous causes and require individualized assessment.

Questions worth taking into care

  1. Is the concern unwanted or distressing to the person?
  2. Are pain, medical conditions, medication, mood, trauma and relationship context assessed?
  3. Has coercion or violence been screened for privately and safely?
  4. Does treatment match a defined diagnosis and patient goal?
  5. Is specialist pelvic, menopause or sexual medicine referral available?

Source record

Evidence used in this review

Sources were selected for clinical authority, methodological relevance and traceability. Links open the original guidance, public-health record or research publication.

  1. [1]
    Defining sexual health

    World Health Organization · 2006

  2. [2]
  3. [3]
  4. [4]
    Female Sexual Dysfunction: ACOG Practice Bulletin 213

    American College of Obstetricians and Gynecologists · 2019

  5. [5]
  6. [6]
    Pelvic floor dysfunction: prevention and non-surgical management

    National Institute for Health and Care Excellence · 2021

Editorial standard

This evidence synthesis is for general information. It does not diagnose a condition or replace care from a qualified health professional. Treatment choices depend on individual history, examination, local guidance and informed preference. Emergency or rapidly worsening symptoms need urgent local medical assessment.